,30 Although no TP53-targeted therapies are currently approved in breast cancer, emerging trials—such as the Phase II study (NCT03358017) of atorvastatin and zoledronic acid—offer potential by targeting the mevalonate pathway and mutant oncogenes. This evidence concerns the gene TP53 and breast carcinoma.